Canada: Canada’s Competition Bureau Releases Updated IP Enforcement Guidelines And White Paper On Patent Litigation Settlement Agreements

The Competition Bureau made several significant announcements in September that affect the pharmaceuticals and life sciences sectors.

On September 18, 2014, the Bureau released the final version of its updated Intellectual Property Enforcement Guidelines (IPEGs), which set out the bureau's approach to navigating the intersection of competition law and intellectual property. Of perhaps greater import, the following week the bureau released a white paper, Patent Litigation Settlement Agreements: A Canadian Perspective, which provides the bureau's first in-depth statement on how it may analyze so-called "pay for delay" settlements under the Competition Act (Act).

IPEGs

As noted in our April 2014 Pharma in brief, the bureau's IPEGs revisions are intended to occur in two phases. The first phase, now complete with the publication of the September 2014 version, involved public consultations on a draft update released in April. This version does not represent a material departure in the approach adopted in 2000 when the IPEGs were first released. The bureau has maintained its position that the circumstances in which it may apply the Act to conduct involving IP or IP rights fall into two broad categories:

  • those involving something more than the mere exercise of the IP right, and
  • those involving the mere exercise of the IP right and nothing else.

The bureau will use the Act's general provisions to address the former circumstances and section 32 (special remedies) to address the latter.

There are several new elements in the September 2014 version, most notably, a reworked discussion of patent pooling arrangements as well as a new discussion of product switching.

It is expected that phase two of the revisions will seek further public comment on additional updates to the IPEGs that will include the bureau's approach to patent litigation settlements, patent assertion entities, and activities related to standard essential patents.

Patent litigation settlements

In conjunction with a keynote address by Commissioner of Competition John Pecman at a pharmaceutical industry conference, the bureau released a white paper that provides background information on the pharmaceutical industry in Canada, the regulatory regime in Canada, the Competition Act provisions that may apply to reverse-payment settlement agreements, and the bureau's preliminary views as to how the Act could apply to such settlements.  

Commissioner Pecman (at least on paper) struck a defiant tone in announcing the bureau's approach to reverse-payment settlements, noting he "completely disagreed" with commentators who have noted that Canada's different regulatory regime merits a "less vigorous" approach to these agreements than in the United States or the European Union. As well, he acknowledged that many would find the bureau's approach "somewhat surprising, particularly in light of the US Supreme Court's recent decision in Actavis."

The white paper's most significant elements are the acknowledgment that the bureau will examine reverse-payment settlement agreements under both the criminal and civil provisions of the Act, and the bureau's call for a notification regime similar to that which exists in the United States.

Application of the Act to Reverse Settlement Agreements

When the US Supreme Court addressed reverse-payment settlements in its Actavis decision, the court found they were subject to a "rule of reason" analysis, which is to say they are not automatically considered anti-competitive, but instead one must examine the likely competitive effects of the agreement. The bureau has adopted a "decidedly different view," according to Commissioner Pecman. The white paper makes clear that the bureau will evaluate settlements under the per se "criminal conspiracy" provision or the "civil abuse of dominance" or "civil agreements with competitors" provisions.

The commissioner said the following settlements would likely attract scrutiny under the criminal provisions:

  • "If a settlement is between competitors and includes conduct with respect to markets or products that are not the focus of the patent litigation or the conduct is beyond the scope of the patent, such as fixing a generic entry date beyond the term of the patent, provided that the conduct is of the type prohibited by this provision."
  • "If there is direct or circumstantial evidence that indicates that the settlement is a vehicle for a 'naked restraint' on competition that is not implemented in furtherance of a legitimate collaboration or was motivated by factors beyond the issues associated with the litigation."

Examples provided include where there is a payment for delayed entry by a generic, with the entry date after the patent's expiry date, or where it is clear that a payment is strictly to delay or prevent entry.

By contrast, where there is no evidence of a "naked restraint," the bureau would most likely review the matter under the civil "agreements between competitors" provision. In certain circumstances, where it appears the parties are abusing their dominant position in a market, the bureau would proceed under the "abuse of dominance" provisions. In both instances, the bureau would need to demonstrate that the settlement agreement would likely cause a substantial lessening or prevention of competition.

Notification system

The bureau attributes its lack of enforcement activity in this area in part to the absence of a notification regime in Canada by which settling parties must advise the government of the settlement. Such a system exists in the United States, where settling parties must file copies of the agreements and provide detailed descriptions of the terms of settlement. The white paper notes that the lack of such a system in Canada "could lead to potentially anticompetitive settlements evading review under the Act," while adopting such a system "would allow us to better protect consumers."

In his remarks, Commissioner Pecman said he will "advocate for better information on patent settlements and the need to explore approaches that could be adapted to Canada's regulatory framework." One is left to wonder whether, in light of the Harper government's stated priority of defending Canadian consumers, legislation to provide for a notification regime can be expected in the government's next budget bill, expected in the spring of 2015. This government has shown a willingness to use omnibus budget legislation to make significant changes to the Competition Act.

In the event a notification regime is adopted, it could have a significant impact on how pharmaceutical companies approach patent litigation settlements in Canada. For those firms operating in North American, its impact may be minimal if they already structure Canadian settlements in a manner similar to contemporaneous US settlements. However, given the differences in Canada's legal regime and the commissioner's remarks, it will remain important to continue to carefully analyze any Canadian settlement to ensure compliance with the Competition Act.

Links

The updated IPEGs may be found here

The Bureau's White Paper on Patent Litigation Settlements may be found here

Norton Rose Fulbright Canada LLP

Norton Rose Fulbright is a global legal practice. We provide the world's pre-eminent corporations and financial institutions with a full business law service. We have more than 3800 lawyers based in over 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.

Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.

Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.

Norton Rose Fulbright LLP, Norton Rose Fulbright Australia, Norton Rose Fulbright Canada LLP, Norton Rose Fulbright South Africa (incorporated as Deneys Reitz Inc) and Fulbright & Jaworski LLP, each of which is a separate legal entity, are members ('the Norton Rose Fulbright members') of Norton Rose Fulbright Verein, a Swiss Verein. Norton Rose Fulbright Verein helps coordinate the activities of the Norton Rose Fulbright members but does not itself provide legal services to clients.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions